Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

Jun 01, 2022 8:00am EDT

Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

May 18, 2022 8:00am EDT

Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 17, 2022 7:00pm EDT

Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders

May 05, 2022 5:00pm EDT

Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights

May 04, 2022 5:00pm EDT

Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

May 02, 2022 4:05pm EDT

Baudax Bio to Present at NobleCon18 Investor Conference

Apr 13, 2022 8:00am EDT

Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results

Mar 16, 2022 8:00am EDT

Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference

Mar 10, 2022 7:00am EST

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery

Mar 08, 2022 8:00am EST